Form SCHEDULE 13D/A Core Scientific, Inc./tx Filed by: Two Seas Capital LP

Item 3 of the Schedule 13D is hereby amended and restated as follows: The aggregate purchase price of the 1,426,299 shares of Common Stock directly held by the Strategic Fund reported herein was $18,541,259. The aggregate purchase price of the 8,988,227 shares of Common Stock, 30,000 options to purchase Common Stock and 313,646 warrants directly held by the Global Fund reported herein was $91,495,610. The aggregate purchase price of the 256,606 shares of Common Stock directly held by the Accounts reported herein was $4,047,562. Further, the securities of the Issuer directly held by the Funds and Accounts were purchased with the working capital of the Funds and Accounts (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business).

Each of the Reporting Persons may be deemed to beneficially own 13,984,778 shares of Common Stock of the Issuer, which includes 313,646 shares of Common Stock issuable upon exercise of warrants and options to purchase 3,000,000 shares of Common Stock. Such amount of beneficial ownership represents approximately 4.4% of the shares of Common Stock outstanding, based on 315,594,802 shares of Common Stock outstanding as of March 23, 2026, based on information disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission ("SEC") on March 31, 2026, plus 313,646 shares of Common Stock issuable upon the exercise of warrants held by the Funds. The Funds and Accounts have delegated to TSC sole voting and investment power over the securities held by the Funds and Accounts pursuant to their respective Investment Management Agreements with TSC. As a result, each of TSC, TSC GP, as the general partner of TSC, and Mr. Toussi, as Chief Investment Officer of TSC and Managing Member of TSC GP, may be deemed to exercise voting and investment power over the securities of the Issuer directly held by the Funds and Accounts. The Funds and Accounts specifically disclaim beneficial ownership of the securities of the Issuer directly held by them by virtue of their inability to vote or dispose of such securities as a result of their respective Investment Management Agreements with TSC. The information in Item 3 regarding the securities held by the Funds and Accounts is incorporated herein by reference. The options to purchase Common Stock consist of options to purchase 2,000,000 shares of Common Stock held by the Global Fund with an exercise price of $18 that expire on May 15, 2026, and options to purchase 1,000,000 shares of Common Stock held by the Global Fund with an exercise price of $22 that expire on September 18, 2026. The Global Fund has also sold options to purchase 2,000,000 shares of Common Stock with an exercise price of $27 that expire on September 18, 2026.

Items 7 through 10 of each of the cover pages of this Schedule 13D are incorporated herein by reference. The information in Item 3 regarding the securities held by the Funds and Accounts is incorporated herein by reference.

Transactions by the Reporting Persons (on behalf of the Funds and Accounts) effected since the previous amendment to Schedule 13D was filed with the SEC on April 16, 2026, are set forth in Exhibit 99.1 and such information is incorporated herein by reference.

The disclosure regarding the relationship between the Reporting Persons in Item 2(c) of this Schedule 13D is incorporated herein by reference. All securities reported in this Schedule 13D are directly held by the Funds and Accounts, each of which are investment management clients of TSC. The limited partners of (or investors in) each of the Funds and Accounts have the right to participate in the receipt of dividends from, or proceeds from the sale of, the securities of the Issuer held for the accounts of their respective Funds or Accounts in accordance with their respective limited partnership interests (or investment percentages) in their respective Funds or Accounts.

The Reporting Persons ceased to be beneficial owners of more than five percent of the Common Stock on April 23, 2026.

Item 6 of this Schedule 13D is supplemented and superseded, as the case may be, as follows: The information in Item 5 of this Schedule 13D is incorporated herein by reference.

99.1 Transactions Effected by the Reporting Persons (on Behalf of the Funds and Accounts) Following April 16, 2026.